Effect of platelet-derived growth factor-BB on bone formation in calvarial defects: an experimental study in rabbits.
The effect of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) on bone healing was examined in calvarial defects in rabbits. Bicortical circular (critical size) defects were prepared in the calvarial bone of 16 rabbits. The defects were closed on the dural side and covered externally with expanded polytetrafluoroethylene membranes to prevent interference with osteogenesis within the defect by the surrounding tissue and to keep the growth factor in place. A single dose of methylcellulose gel (4.4%) with (n = 8) or without rhPDGF-BB (50 micrograms/ml) (n = 8) was applied to the defects, and the bone formation was evaluated after 8 weeks. Healing of defects in both groups was characterized by the presence of newly formed bone along the edges of the original defect and by a central area of fibrous connective tissue. The newly formed bone in the rhPDGF-BB treated defects had a trabecular structure; in contrast, a more compact structure was found in the control defects. In the rhPDGF-BB-treated defects, the bone ingrowth was 51.8 +/- 7.1% compared to 30.5 +/- 3.3% in the control defects. Furthermore, the amount of mineralized tissue was increased 112% in the rhPDGF-BB group. The amount of bone marrow was increased 75% in the rhPDGF-BB-treated defect. The porosity of cortical lamella in the newly formed bone was 84% higher in the rhPDGF-BB-treated defects compared to the control. These results show that administration of a single dose of rhPDGF-BB stimulates bone formation in critical size calvarial defects.
Vikjaer
D
D
Department of Oral and Maxillofacial Surgery, School of Dentistry, Faculty of Health Sciences, University of Copenhagen, Denmark.
Blom
S
S
Hjørting-Hansen
E
E
Pinholt
E M
EM
D000818:Animals; D000077214:Becaplermin; D001847:Bone Diseases / Q000188:drug therapy / Q000473:pathology; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002113:Calcification, Physiologic / Q000187:drug effects; D003238:Connective Tissue / Q000187:drug effects / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D006133:Growth Substances / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008567:Membranes, Artificial; D008747:Methylcellulose; D010012:Osteogenesis / Q000187:drug effects*; D010592:Pharmaceutic Aids; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D011138:Polytetrafluoroethylene; D016062:Porosity; D020574:Proto-Oncogene Proteins c-sis; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins; D012886:Skull / Q000187:drug effects* / Q000473:pathology; D014945:Wound Healing / Q000187:drug effects
D005782:Gels; D006133:Growth Substances; D008567:Membranes, Artificial; D010592:Pharmaceutic Aids; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin; D011138:Polytetrafluoroethylene; D008747:Methylcellulose